KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

BeOne Medicines (ONC) EBIT Margin: 2015-2025

Historic EBIT Margin for BeOne Medicines (ONC) over the last 10 years, with Sep 2025 value amounting to 11.55%.

  • BeOne Medicines' EBIT Margin rose 2356.00% to 11.55% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.67%, marking a year-over-year increase of 2998.00%. This contributed to the annual value of -14.91% for FY2024, which is 3421.00% up from last year.
  • According to the latest figures from Q3 2025, BeOne Medicines' EBIT Margin is 11.55%, which was up 72.85% from 6.68% recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' EBIT Margin registered a high of 89.06% during Q4 2021, and its lowest value of -316.58% during Q2 2021.
  • Its 3-year average for EBIT Margin is -23.66%, with a median of -12.01% in 2024.
  • In the last 5 years, BeOne Medicines' EBIT Margin surged by 72,953bps in 2021 and then slumped by 21,235bps in 2022.
  • BeOne Medicines' EBIT Margin (Quarterly) stood at 89.06% in 2021, then crashed by 21,235bps to -123.29% in 2022, then soared by 6,279bps to -60.50% in 2023, then soared by 5,345bps to -7.04% in 2024, then skyrocketed by 2,356bps to 11.55% in 2025.
  • Its EBIT Margin was 11.55% in Q3 2025, compared to 6.68% in Q2 2025 and 0.99% in Q1 2025.